ERBB2 and gastroesophageal junction adenocarcinoma: This phase II trial investigated the use of pembrolizumab in patients with gastric/GEJ adenocarcinoma previously treated with two or more systemic therapies including fluoropyrimidine and a platinum-based therapy, and a HER2/neu therapy if applicable.